Voltage-gated sodium channel blockers for the treatment of neuropathic pain

Expert Review of Neurotherapeutics

Volumn 7, Issue 11, 2007, Pages 1597-1612

  Cummins, Theodore R ^a   Rush, Anthony M ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEUROSOLUTIONS LTD   (United Kingdom)

Author keywords

Analgesia; Analgesic; Local anesthetic; Neuropathic pain; Nociceptive neuron; Sodium channel blocker; Voltage gated sodium channel

Indexed keywords

2 [4 (4 CHLORO 2 FLUOROPHENOXY)PHENYL]PYRIMIDINE 4 CARBOMAXAMIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BUPIVACAINE; CARBAMAZEPINE; CLOMIPRAMINE; CONOTOXIN; CYCLOPENTANE DERIVATIVE; CYCLOPENTANE DICARBOXAMIDE; DESIPRAMINE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MAPROTILINE; MEXILETINE; NORTRIPTYLINE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; SAXITOXIN; SODIUM CHANNEL BLOCKING AGENT; TETRODOTOXIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ALLODYNIA; ATAXIA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERALGESIA; LOW BACK PAIN; NERVE CELL EXCITABILITY; NEUROPATHIC PAIN; NEUROTOXICITY; NOCICEPTION; NONHUMAN; REVIEW; SKIN IRRITATION; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT;

HUMANS; ION CHANNEL GATING; NEURALGIA; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 36148978879     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.11.1597     Document Type: Review

References (190)

1. Backonja MM. Defining neuropathic pain. Anesth. Analg. 97(3), 785-790 (2003).
2. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin. Ther. 26(7), 951-979 (2004).
3. Djouhri L, Dawbarn D, Robertson A, Newton R, Lawson SN. Time course and nerve growth factor dependence of inflammation-induced alterations in electrophysiological membrane properties in nociceptive primary afferent neurons. J. Neurosci. 21, 8722-8733 (2001).
4. Wall PD, Gutnick M. Ongoing activity in peripheral nerves: the physiology and pharmacology of impulses originating from a neuroma. Exp. Neurol. 43(3), 580-593 (1974).
5. Zhang JM, Donnelly DF, Song XJ, Lamotte RH. Axotomy increases the excitability of dorsal root ganglion cells with unmyelinated axons. J. Neurophysiol. 78(5), 2790-2794 (1997).
6. Zhang JM, Song XJ, LaMotte RH. An in vitro study of ectopic discharge generation and adrenergic sensitivity in the intact, nerve-injured rat dorsal root ganglion. Pain 72, 51-57 (1997).
7. Kim YI, Na HS, Kim SH et al. Cell type-specific changes of the membrane properties of peripherally-axotomized dorsal root ganglion neurons in a rat model of neuropathic pain. Neuroscience 86, 301-309 (1998).
8. Ma C, Lamotte RH. Enhanced excitability of dissociated primary sensory neurons after chronic compression of the dorsal root ganglion in the rat. Pain 113(1-2), 106-112 (2005).
9. Xu GY, Zhao ZQ. Change in excitability and phenotype of substance P and its receptor in cat A? sensory neurons following peripheral inflammation. Brain Res. 923, 112-119 (2001).
10. Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain 87(1), 7-17 (2000).
11. Strichartz GR, Zhou Z, Sinnott C, Khodorova A. Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain. Novartis Found. Symp. 241, 189-201 (2002).
12. Massey GV, Pedigo S, Dunn NL, Grossman NJ, Russell EC. Continuous lidocaine infusion for the relief of refractory malignant pain in a terminally ill pediatric cancer patient. J. Pediatr. Hematol. Oncol. 24, 566-568 (2002).
13. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26, 13-25 (2000).
14. Goldin AL. Resurgence of sodium channel research. Annu. Rev. Physiol. 63, 871-894 (2001).
15. Amir R, Argoff CE, Bennett GJ et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain 7(5 Suppl. 3), S1-S29 (2006).
16. Rush AM, Cummins TR, Waxman SG. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J. Physiol. 579(1), 1-14 (2007).
17. George AL Jr. Inherited disorders of voltage-gated sodium channels. J. Clin. Invest. 115(8), 1990-1999 (2005).
18. Waxman SG. Transcriptional channelopathies: an emerging class of disorders. Nat. Rev. Neurosci. 2(9), 652-659 (2001).
19. v1.7 sodium channels in mouse spinal sensory neurons. J. Physiol. 551(3), 741-750 (2003).
20. Isom LL. Sodium channel β-subunits: anything but auxiliary. Neuroscientist 7(1), 42-54 (2001).
21. Yu FH, Westenbroek RE, Silos-Santiago I et al. Sodium channel β4, a new disulfide-linked auxiliary subunit with similarity to β2. J. Neurosci. 23(20), 7577-7585 (2003).
22. Goldin AL, Barchi RL, Caldwell JH et al. Nomenclature of voltage-gated sodium channels. Neuron 28, 365-368 (2000).
23. Akopian AN, Souslova V, Sivilotti L, Wood JN. Structure and distribution of a broadly expressed atypical sodium channel. FEBS Lett. 400(2), 183-187 (1997).
24. x channel involved in CNS sodium-level sensing. Nat. Neurosci. 5(6), 511-512 (2002).
25. Felts PA, Yokoyama S, Dib-Hajj S, Black JA, Waxman SG. Sodium channel α-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system. Mol. Brain Res. 45, 71-82 (1997).
26. Trimmer JS, Rhodes KJ. Localization of voltage-gated ion channels in mammalian brain. Annu. Rev. Physiol. 66, 477-519 (2004).
27. v 1.5 underlies the 'third TTX-R sodium current' in rat small DRG neurons. Brain Res. Mol. Brain Res. 106(1-2), 70-82 (2002).
28. Black JA, Dib-Hajj S, McNabola K et al. Spinal sensory neurons express multiple sodium channel α-subunit mRNAs. Brain Res. Mol. Brain Res. 43(1-2), 117-131 (1996).
29. Amaya F, Decosterd I, Samad TA et al. Diversity of expression of the sensory neuron-specific TTX-resistant voltage-gated sodium ion channels SNS and SNS2. Mol. Cell Neurosci. 15(4), 331-342 (2000).
30. Beckh S, Noda M, Lubbert H, Numa S. Differential regulation of three sodium channel messenger RNAs in the rat central nervous system during development. EMBO J. 8(12), 3611-3616 (1989).
31. Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is re-expressed following axotomy. J. Neurophysiol. 72, 466-470 (1994).
32. Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB. Potent analgesic effects of GDNF in neuropathic pain states. Science 290(5489), 124-127 (2000).
33. 2+ exchanger. Proc. Natl Acad. Sci. USA 101(21), 8168-8173 (2004).
34. Catterall WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol. 79, 441-456 (1999).
35. Cestele S, Catterall WA. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 82(9-10), 883-892 (2000).
36. + channel outer vestibule. Biophys. J. 75(6), 2647-2657 (1998).
37. Leffler A, Herzog RI, Dib-Hajj SD, Waxman SG, Cummins TR. Pharmacological properties of neuronal TTX-resistant sodium channels and the role of a critical serine pore residue. Pflugers Arch. 451(3), 454-463 (2005).
38. Satin J, Kyle JW, Chen M et al. A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science 256, 1202-1205 (1992).
39. Sivilotti L, Okuse K, Akopian AN, Moss S, Wood JN. A single serine residue confers tetrodotoxin insensitivity on the rat sensory-neuron-specific sodium channel SNS. FEBS Lett. 409, 49-52 (1997).
40. Cummins TR, Aglieco F, Dib-Hajj SD. Critical molecular determinants of voltage-gated sodium channel sensitivity to μ-conotoxins GIIIA/B. Mol. Pharmacol. 61, 1192-1201 (2002).
41. + channels. J. Biol. Chem. 278(10), 8717-8724 (2003).
42. Jain KK. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opin. Investig. Drugs 9(10), 2403-2410 (2000).
43. v1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc. Natl Acad. Sci. USA 103(45), 17030-17035 (2006).
44. v1.8 and has a long-lasting analgesic activity. Biochemistry 45(23), 7404-7414 (2006).
45. Blumenthal KM, Seibert AL. Voltage-gated sodium channel toxins: poisons, probes, and future promise. Cell Biochem. Biophys. 38(2), 215-238 (2002).
46. Liang S. An overview of peptide toxins from the venom of the Chinese bird spider Selenocosmia huwena Wang [=Ornithoctonus huwena (Wang)]. Toxicon 43, 575-585 (2004).
47. Middleton RE, Warren VA, Kraus RL et al. Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry 41(50), 14734-14747 (2002).
48. Clare JJ, Tate SN, Nobbs M, Romanos MA. Voltage-gated sodium channels as therapeutic targets. Drug Discov. Today 5, 506-520 (2000).
49. Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res. Brain Res. Rev. 26(1), 16-28 (1998).
50. + channels. Proc. Natl Acad. Sci. USA 93(17), 9270-9275 (1996).
51. + channel α subunit. J. Biol. Chem. 276(1), 20-27 (2001).
52. + channel α subunit in voltage-dependent gating and drug block. J. Biol. Chem. 277, 35393-35401 (2002).
53. + channels. J. Membr. Biol. 201(1), 1-8 (2004).
54. Sills GJ, Brodie MJ. Update on the mechanisms of action of antiepileptic drugs. Epileptic Disord. 3(4), 165-172 (2001).
55. Ritter AM, Ritchie C, Martin WJ. Relationship between the firing frequency of injured peripheral neurons and inhibition of firing by sodium channel blockers. J. Pain 8(4), 287-295 (2007).
56. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13(1), 21-42 (2007).
57. Kawagoe H, Yamaoka K, Kinoshita E et al. Molecular basis for exaggerated sensitivity to mexiletine in the cardiac isoform of the fast Na channel. FEBS Lett. 513(2-3), 235-241 (2002).
58. + channels. J. Pharmacol. Exp. Ther. 320(1), 354-364 (2007).
59. Rush AM, Elliott JR. Phenytoin and carbamazepine: differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia. Neurosci. Lett. 226(2), 95-98 (1997).
60. Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr. Opin. Neurobiol. 13(3), 291-297 (2003).
61. Wu G, Ringkamp M, Murinson BB et al. Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J. Neurosci. 22(17), 7746-7753 (2002).
62. Liu CN, Michaelis M, Amir R, Devor M. Spinal nerve injury enhances subthreshold membrane potential oscillations in DRG neurons: relation to neuropathic pain. J. Neurophysiol. 84(1), 205-215 (2000).
63. Michaelis M, Liu X, Janig W. Axotomized and intact muscle afferents but no skin afferents develop ongoing discharges of dorsal root ganglion origin after peripheral nerve lesion. J. Neurosci. 20(7), 2742-2748 (2000).
64. Lai J, Porreca F, Hunter JC, Gold MS. Voltage-gated sodium channels and hyperalgesia. Annu. Rev. Pharmacol. Toxicol. 44, 371-397 (2004).
65. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 48(2), 261-268 (1992).
66. Yang Y, Wang Y, Li S et al. Mutations in SCN9A, encoding a sodium channel α-subunit, in patients with primary erythermalgia. J. Med. Genet. 41, 171-174 (2004).
67. v1.7. Arch. Neurol. 62, 1587-1590 (2005).
68. v1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128, 1847-1854 (2005).
69. v1.7. Ann. Neurol. 59, 553-558 (2006).
70. v1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J. Neurosci. 26, 12566-12575 (2006).
71. Lee MJ, Yu HS, Hsieh ST, Stephenson DA, Lu CJ, Yang CC. Characterization of a familial case with primary erythromelalgia from Taiwan. J. Neurol. 254, 210-214 (2007).
72. v1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 24(38), 8232-8236 (2004).
73. v1.7 alters channel gating. J. Biol. Chem. 281(47), 36029-36035 (2006).
74. v1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J. Physiol. 581(3), 1019-1031 (2007).
75. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl Acad. Sci. USA 103(21), 8245-8250 (2006).
76. Fertleman CR, Baker MD, Parker KA et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52(5), 767-774 (2006).
77. Cox JJ, Reimann F, Nicholas AK et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894-898 (2006).
78. Ahmad S, Dahllund L, Eriksson AB et al. A stop codon mutation in SCN9A causes lack of pain sensation. Hum. Mol. Genet. 16(17), 2114-2121 (2007).
79. v1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71(4), 311-319 (2007).
80. Toledo-Aral JJ, Moss BL, He ZJ et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc. Natl Acad. Sci. USA 94(4), 1527-1532 (1997).
81. + channel α subunit protein. J. Physiol. 546(2), 565-576 (2003).
82. v1.7 (PN1) in acute and inflammatory pain. Proc. Natl Acad. Sci. USA 101(34), 12706-12711 (2004).
83. Cummins TR, Waxman SG. Down-regulation of tetrodotoxin-resistant sodium currents and up-regulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 17, 3503-3514 (1997).
84. Rush AM, Brau ME, Elliott AA, Elliott JR. Electrophysiological properties of sodium current subtypes in small cells from adult rat dorsal root ganglia. J. Physiol. 511(3), 771-789 (1998).
85. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379, 257-262 (1996).
86. Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc. Natl Acad. Sci. USA 95, 8963-8968 (1998).
87. Tate S, Benn S, Hick C et al. Two sodium channels contribute to the TTX-R sodium current in primary sensory neurons. Nat. Neurosci. 1, 653-655 (1998).
88. Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN, Waxman SG. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J. Neurosci. 19(24), RC43 (1999).
89. v1.9 to sensory transmission and nociceptive behavior. Proc. Natl Acad. Sci. USA 102, 9382-9387 (2005).
90. v1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci. 26(50), 12852-12860 (2006).
91. v1.9: a sodium channel with unique properties. Trends Neurosci. 25(5), 253-259 (2002).
92. v1.9 subunit in myenteric sensory neurons. J. Neurosci. 23, 2715-2725 (2003).
93. + current affects resting potential and response to depolarization in simulated spinal sensory neurons. J. Neurophysiol. 86, 1351-1364 (2001).
94. v1.9 (NaN) in nociceptive primary afferent neurons. J. Neurosci. 22(17), 7425-7433 (2002).
95. v1.9 sodium current in mouse DRG neurons via G-proteins. Brain Res. 1023(2), 264-271 (2004).
96. + currents and inflammatory hyperalgesia. Proc. Natl Acad. Sci. USA 96(14), 7645-7649 (1999).
97. v1.8. Pain 95(1-2), 143-152 (2002).
98. v1.8 in uninjured axons enables neuropathic pain. J. Neurosci. 23(1), 158-166 (2003).
99. v1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience 146(2), 812-821 (2007).
100. v1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 86(2), 629-640 (2001).
101. Akopian AN, Souslova V, England S et al. The tetrodotoxin- resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. 2, 541-548 (1999).
102. Khasar SG, Gold MS, Levine JD. A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. Neurosci. Lett. 256, 17-20 (1998).
103. v1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain 123, 75-82 (2006).
104. + current in nociceptors. Proc. Natl Acad. Sci. USA 93, 1108-1112 (1996).
105. + current in rat sensory neurons. J. Physiol. 544, 385-402 (2002).
106. Zhang YH, Fehrenbacher JC, Vasko MR, Nicol GD. Sphingosine-1-phosphate via activation of a G-protein-coupled receptor(s) enhances the excitability of rat sensory neurons. J. Neurophysiol. 96, 1042-1052 (2006).
107. v1.8 in NGF-induced hyperalgesia, but not neuropathic pain. Neuroreport 12, 3077-3080 (2001).
108. v1.8. Mol. Pain 1, 24 (2005).
109. v1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl Acad. Sci. USA 104(20), 8520-8525 (2007).
110. v1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. 23(26), 8881-8892 (2003).
111. v1.3 null mutant mice. Mol. Pain 2, 33 (2006).
112. Amir R, Liu CN, Kocsis JD, Devor M. Oscillatory mechanism in primary sensory neurones. Brain 125(2), 421-435 (2002).
113. Fozzard HA, Lee PJ, Lipkind GM. Mechanism of local anesthetic drug action on voltage-gated sodium channels. Curr. Pharm. Des. 11(21), 2671-2686 (2005).
114. Yanagidate F, Strichartz GR. Local anesthetics. Handb. Exp. Pharmacol. 177, 95-127 (2007).
115. Scholz A, Vogel W. Tetrodotoxin-resistant action potentials in dorsal root ganglion neurons are blocked by local anesthetics. Pain 89(1), 47-52 (2000).
116. + currents in rat sensory neurons. Anesthesiology 94(1), 137-144 (2001).
117. Persaud N, Strichartz GR. Micromolar lidocaine selectively blocks propagating ectopic impulses at a distance from their site of origin. Pain 99(1-2), 333-340 (2002).
118. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous idocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 38(3), 333-338 (1989).
119. Smith LJ, Shih A, Miletic G, Miletic V. Continual systemic infusion of lidocaine provides analgesia in an animal model of neuropathic pain. Pain 97(3), 267-273 (2002).
120. Meier T, Wasner G, Faust M et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 106(1-2), 151-158 (2003).
121. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch. Neurol. 61(6), 914-918 (2004).
122. Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 6(5), 379-384 (2005).
123. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin. J. Pain 18(5), 297-301 (2002).
124. Hans GH, Robert DN, Van Maldeghem KN. Treatment of an acute severe central neuropathic pain syndrome by topical application of lidocaine 5% patch: a case report. Spinal Cord (2007) (Epub ahead of print).
125. Hines R, Keaney D, Moskowitz MH, Prakken S. Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med. 3(4), 361-365 (2002).
126. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J. Clin. Pharmacol. 43(2), 111-117 (2003).
127. Tremont-Lukats IW, Hutson PR, Backonja MM. A randomized, double-masked, placebo-controlled pilot trial of extended iv lidocaine infusion for relief of ongoing neuropathic pain. Clin. J. Pain 22(3), 266-271 (2006).
128. Bean BP, Cohen CJ, Tsien RW. Lidocaine block of cardiac sodium channels. J. Gen. Physiol. 81(5), 613-642 (1983).
129. Gottrup H, Bach FW, Juhl G, Jensen TS. Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. Anesthesiology 104(3), 527-536 (2006).
130. Hollmann MW, Gross A, Jelacin N, Durieux ME. Local anesthetic effects on priming and activation of human neutrophils. Anesthesiology 95(1), 113-122 (2001).
131. Hollmann MW, Ritter CH, Henle P, de Klaver M, Kamatchi GL, Durieux ME. Inhibition of m3 muscarinic acetylcholine receptors by local anaesthetics. Br. J. Pharmacol. 133(1), 207-216 (2001).
132. Hollmann MW, McIntire WE, Garrison JC, Durieux ME. Inhibition of mammalian Gq protein function by local anesthetics. Anesthesiology 97(6), 1451-1457 (2002).
133. Benkwitz C, Garrison JC, Linden J, Durieux ME, Hollmann MW. Lidocaine enhances G?i protein function. Anesthesiology 99(5), 1093-1101 (2003).
134. Hollmann MW, Herroeder S, Kurz KS et al. Time-dependent inhibition of G protein-coupled receptor signaling by local anesthetics. Anesthesiology 100(4), 852-860 (2004).
135. Tzeng JI, Cheng KI, Huang KL et al. The cutaneous analgesic effect of class I antiarrhythmic drugs. Anesth. Analg. 104(4), 955-958 (2007).
136. + channel blockers in two rat models of neuropathic pain. Eur. J. Pharmacol. 458(3), 275-282 (2003).
137. Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 20(10), 1594-1597 (1997).
138. Adriaensen H, Plaghki L, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes Metab. Res. Rev. 21(3), 231-240 (2005).
139. Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67(9), 1265-1289 (2007).
140. Lipkind GM, Fozzard HA. Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol. Pharmacol. 68(6), 1611-1622 (2005).
141. v1.8-like sodium channels. Neurosci. Lett. 408(2), 129-134 (2006).
142. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst. Rev. 3, CD005451 (2005).
143. Beydoun A, Kutluay E. Oxcarbazepine. Expert Opin. Pharmacother. 3(1), 59-71 (2002).
144. Jang Y, Kim ES, Park SS, Lee J, Moon DE. The suppressive effects of oxcarbazepine on mechanical and cold allodynia in a rat model of neuropathic pain. Anesth. Analg. 101(3), 800-806 (2005).
145. Magenta P, Arghetti S, Di Palma F et al. Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurol. Sci. 26(4), 218-226 (2005).
146. Solaro C, Restivo D, Mancardi GL, Tanganelli P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol. Sci. 28(3), 156-158 (2007).
147. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol. Scand. 113(6), 395-404 (2006).
148. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur. J. Pain 9(5), 543-554 (2005).
149. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol. Scand. 114(3), 177-180 (2006).
150. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res. 13(2), 107-112 (1992).
151. Vinik AI, Tuchman M, Safirstein B et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 128(1-2), 169-179 (2007).
152. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. 6(3), 225-234 (2005).
153. Hofer D, Lohberger B, Steinecker B, Schmidt K, Quasthoff S, Schreibmayer W. A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms. Eur. J. Pharmacol. 538(1-3), 5-14 (2006).
154. Kishore-Kumar R, Max MB, Schafer SC et al. Desipramine relieves postherpetic neuralgia. Neurology 47, 305-312 (1990).
155. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 38, 1427-1432 (1998).
156. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 32, 671-673 (1982).
157. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin. Pharmacol. Toxicol. 96(6), 399-409 (2005).
158. Chen YW, Huang KL, Liu SY et al. Intrathecal tri-cyclic antidepressants produce spinal anesthesia. Pain 112(1-2), 106-112 (2004).
159. + channels in rat dorsal root ganglion neurons. Eur. J. Pharmacol. 401(3), 297-305 (2000).
160. + channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 110, 166-174 (2004).
161. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J. Pain 8(4), 315-324 (2007).
162. Nau C, Seaver M, Wang SY, Wang GK. Block of human heart hH1 sodium channels by amitriptyline. J. Pharmacol. Exp. Ther. 292(3), 1015-1023 (2000).
163. v1.4 sodium channels by trifluoperazine involves the local anesthetic receptor. J. Neurophysiol. 96(4), 1848-1859 (2006).
164. Golbidi S, Moriuchi H, Irie T, Ghafghazi T, Hajhashemi V. Involvement of calmodulin inhibition in analgesia induced with low doses of intrathecal trifluoperazine. Jpn J. Pharmacol. 88(2), 151-157 (2002).
165. Levin RM, Weiss B. Selective binding of antipsychotics and other psychoactive agents to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. J. Pharmacol. Exp. Ther. 208(3), 454-459 (1979).
166. Ilyin VI, Hodges DD, Whittemore ER, Carter RB, Cai SX, Woodward RM. V102862 (Co 102862): a potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels. Br. J. Pharmacol. 144(6), 801-812 (2005).
167. Ilyin VI, Pomonis JD, Whiteside GT et al. Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states. J. Pharmacol. Exp. Ther. 318(3), 1083-1093 (2006).
168. Ko SH, Jochnowitz N, Lenkowski PW et al. Reversal of neuropathic pain by α-hydroxyphenylamide: a novel sodium channel antagonist. Neuropharmacology 50(7), 865-873 (2006).
169. Jones PJ, Wang Y, Smith MD et al. Hydroxyamide analogs of propofol exhibit state-dependent block of sodium channels in hippocampal neurons: implications for anticonvulsant activity. J. Pharmacol. Exp. Ther. 320(2), 828-836 (2007).
170. + currents in dorsal root ganglion neurons. Eur. J. Pharmacol. 510(3), 197-208 (2005).
171. Kyle DJ, Ilyin VI. Sodium channel blockers. J. Med. Chem. 50(11), 2583-2588 (2007).
172. Brochu RM, Dick IE, Tarpley JW et al. Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. Mol. Pharmacol. 69(3), 823-832 (2006).
173. v1.7 blockers: potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 17(16), 4630-4634 (2007).
174. Stohr T, Kupferberg HJ, Stables JP et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74(2-3), 147-154 (2007).
175. Hao JX, Stohr T, Selve N, Wiesenfeld-Hallin Z, Xu XJ. Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur. J. Pharmacol. 553(1-3), 135-140 (2006).
176. Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur. J. Pharmacol. 539(1-2), 64-70 (2006).
177. Beyreuther BK, Callizot N, Brot MD, Feldman R, Bain SC, Stohr T.
178. Errington AC, Coyne L, Stohr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50(8), 1016-1029 (2006).
179. Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a Phase II double-blind placebo-controlled study. Clin. J. Pain 23(2), 150-158 (2007).
180. Omana-Zapata I, Khabbaz MA, Hunter Clarke DE, Bley KR. Tetrodotoxin inhibits neuropathic ectopic activity in neuromas, dorsal root ganglia and dorsal horn neurons. Pain 72(1-2), 41-49 (1997).
181. Marcil J, Walczak JS, Guindon J, Ngoc AH, Lu S, Beaulieu P. Antinociceptive effects of tetrodotoxin (TTX) in rodents. Br. J. Anaesth. 96(6), 761-768 (2006).
182. Rodriguez-Navarro AJ, Lagos N, Lagos M et al. Neosaxitoxin as a local anesthetic: preliminary observations from a first human trial. Anesthesiology 106(2), 339-345 (2007).
183. Kohane DS, Smith SE, Louis DN et al. Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain 104(1-2), 415-421 (2003).
184. Kohane DS, Yieh J, Lu NT, Langer R, Strichartz GR, Berde CB. A re-examination of tetrodotoxin for prolonged duration local anesthesia. Anesthesiology 89(1), 119-131 (1998).
185. v1.6 Voltage dependent sodium channel. Am. J. Physiol. Cell Physiol. 293(2), C783-C789 (2007).
186. v1.7 sodium channels in primary afferents. Hum. Gene Ther. 16(2), 271-277 (2005).
187. v1.8 tetrodotoxin-resistant voltage-gated sodium channel in dorsal root ganglion neurons. Anesthesiology 103(4), 828-836 (2005).
188. Shah BS, Stevens EB, Gonzalez MI et al. β3, a novel auxiliary subunit for the voltage-gated sodium channel, is expressed preferentially in sensory neurons and is upregulated in the chronic constriction injury model of neuropathic pain. Eur. J. Neurosci. 12, 3985-3990 (2000).
189. Lopez-Santiago LF, Pertin M, Morisod X et al. Sodium channel β2 subunits regulate tetrodotoxin-sensitive sodium channels in small dorsal root ganglion neurons and modulate the response to pain. J. Neurosci. 26(30), 7984-7994 (2006).
190. Hong S, Morrow TJ, Paulson PE, Isom LL, Wiley JW. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and - resistant sodium channels in dorsal root ganglion neurons in the rat. J. Biol. Chem. 279(28), 29341-29350 (2004).